Type I Collagen Diseases Osteogenesis Imperfecta

Slide 1 · Type I Collagen Diseases

Osteogenesis Imperfecta

A pathology lecture on molecular matrix defects and skeletal fragility

Normal collagen matrix

Organized organic scaffold

Defective collagen matrix

Lower mechanical competence

Schematic comparison

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Osteogenesis imperfecta: A collagenopathy

Bone fragility begins in the extracellular matrix.

Inherited connective-tissue disorder with pronounced skeletal fragility.

Type I collagen abnormalities explain most cases.

The phenotype spans mild childhood fractures to severe congenital deformity.

Slide 3 · Learning outcomes

Explain how type I collagen supports skeletal strength.

Relate collagen quantity and quality defects to clinical severity.

Recognize skeletal and extraskeletal manifestations.

Use traditional clinical subtypes without mistaking them for unique genotypes.

Slide 4 · Why this is a systemic disease

Bone is the dominant clinical target.

Type I collagen is also important in sclerae, dentin, ligaments, skin, and ear structures.

A molecular matrix defect therefore produces multiorgan features.

Type I collagen defect

Altered tissue matrix

Bone + extraskeletal signs

Slide 5 · Bone matrix: A composite material

Collagen

Organic framework

Type I collagen-rich osteoid

Contributes tensile resilience

Mineral

Mineral phase

Calcium-phosphate crystals

Contributes compressive stiffness

Slide 6 · Type I collagen is a triple helix

Three pro-α chains assemble into one procollagen molecule.

The usual composition is two α1(I) chains and one α2(I) chain.

Correct folding is required for export and extracellular fibril assembly.

Triple-helix organization

2 × α1(I) chains

1 × α2(I) chain

Slide 7 · Two genes encode the principal chains

COL1A1 encodes the pro-α1(I) collagen chain.

COL1A2 encodes the pro-α2(I) collagen chain.

Variants in either gene may alter collagen abundance or structure.

COL1A1 / COL1A2

Pro-α chains

Type I collagen fibril

Slide 8 · The glycine requirement

The collagen helix repeats the Gly–X–Y amino-acid pattern.

Small glycine residues occupy the tight core of the triple helix.

Substitution with a larger residue can compromise helix formation.

Gly–X–Y repeat

Glycine substitution

Helix misfolding

Slide 9 · Collagen assembly is multistage

Chain synthesis

Helix formation

Secretion

Fibril assembly

Pro-α chains are synthesized and assembled intracellularly.

Triple-helix formation precedes secretion.

Extracellular processing and fibril organization produce a functioning matrix.

Slide 10 · The core pathogenic sequence

A pathogenic collagen variant perturbs chain production or assembly.

The skeletal organic matrix becomes quantitatively insufficient or structurally weak.

Fragility fractures result under lower mechanical loads.

Pathogenic variant

Abnormal collagen matrix

Fragility fractures

Slide 11 · Type I OI often reflects a quantity defect

Quantity defect

Lower production

Fewer normal molecules

Often milder phenotype

Quality defect

Structural disruption

Abnormal collagen molecules

Often greater severity

Slide 12 · Dominant-negative collagen variants

Some mutant α chains participate in triple-helix assembly.

Their incorporation can impair structures that also contain normal chains.

Consequently, one pathogenic allele may disrupt many collagen molecules.

Mutant chain joins helix

Mixed helix disrupted

Matrix structure impaired

Slide 13 · Haploinsufficiency and dominant negativity

Haploinsufficiency

Reduced output

Normal collagen quality

Often type I pattern

Dominant-negative effect

Abnormal product

Interference with assembly

Severe forms possible

Slide 14 · Most OI is COL1A1/COL1A2 related

COL1A1

COL1A2

Other OI genes

Approximately 80%–90% of cases to dominant collagen-chain gene variants.

Other genes account for a smaller proportion of cases.

Variant mechanisms differ even when clinical features overlap.

Slide 15 · Beyond collagen structural genes

Some less-common genes act on collagen biosynthesis or processing.

Other genes affect osteoblast signaling or mineralization.

Not all molecularly established OI is caused by a COL1A1/COL1A2 variant.

Collagen processing

Osteoblast signaling

Mineralization pathways

Slide 16 · Inheritance patterns require molecular context

Familial presentation

Inherited dominant variant

May affect successive generations

Expression can vary

Sporadic presentation

De novo variant

May present as simplex case

Family history can be negative

Slide 17 · Family history is not a diagnostic gate

A positive family history supports a hereditary collagenopathy.

A negative family history does not exclude OI.

Clinical signs, imaging, and molecular findings must be integrated.

Clinical suspicion

Imaging evidence

Genetic evaluation

Slide 18 · A common final pathway: Too little bone

Fragility reflects defective skeletal architecture and matrix.

The fundamental skeletal abnormality as reduced bone amount.

Insufficient or abnormal osteoid matrix lowers mechanical competence.

A low-energy fracture may be the first recognized manifestation.

Slide 19 · Fragility is a mechanical consequence

Bone may fracture with minor trauma—or without recognized trauma.

Repeated fractures can generate deformity and limit mobility.

Fracture history must be interpreted alongside age and phenotype.

Weak matrix

Low-load fracture

Cumulative deformity

Slide 20 · Long bones: The principal fracture setting

Long-bone fractures are common because limbs experience repeated loading.

Healing fractures may coexist with bowing or deformity in severe phenotypes.

The burden of fractures varies markedly across the clinical spectrum.

Slide 21 · Vertebral disease contributes to morbidity

Fragility may affect vertebral bodies, producing compression deformities.

Vertebral distortion can alter spinal curvature and stature.

Severe phenotypes can develop progressive kyphoscoliosis.

Weak vertebral bodies

Compression deformity

Spinal curvature

Slide 22 · Growth impairment tracks severity

Lower severity

Mild OI

Near-normal stature

Less skeletal distortion

Higher severity

Severe OI

Marked short stature

Recurrent fracture/deformity

Slide 23 · Prenatal disease is a severity marker

Fetal fractures

Bone shortening

Thoracic compromise

High perinatal risk

The most severe presentations may include fractures before birth.

Bowing and shortening of long bones may be visible on fetal imaging.

Thoracic and rib abnormalities contribute to respiratory risk.

Slide 24 · Blue sclerae: A tissue transparency sign

Type I collagen contributes to scleral opacity.

Decreased collagen can increase scleral translucency.

Underlying choroidal pigment is more visible, producing a blue appearance.

Layer schematic — not a histologic section

Higher collagen content

Underlying choroid

Reduced collagen content

Underlying choroid

Slide 25 · Blue sclerae are useful but not universal

Feature present

Blue/gray sclerae

Supportive clue

Common in type I

Feature absent

Normal sclerae

Do not exclude disease

May occur in type IV

Slide 26 · Dentinogenesis imperfecta

Abnormal dentin matrix changes tooth shape and translucency.

Affected teeth may be discolored, fragile, and susceptible to wear.

Dental signs support a generalized type I collagen defect.

Deficient dentin matrix

Translucent/discolored teeth

Wear and breakage

Slide 27 · Hearing loss has mixed mechanisms

Conduction

Conductive component

Ossicular / middle-ear abnormalities

Sound transmission impaired

Sensorineural

Sensorineural component

Inner-ear involvement

Sound processing impaired

Slide 28 · Joint and soft-tissue manifestations

Joint laxity

Skin involvement

Dental / ear signs

Ligamentous laxity can accompany collagen abnormalities.

Skin and other connective tissues may be involved.

Extraosseous findings help unify a seemingly skeletal presentation.

Slide 29 · The phenotype is a continuum

Clinical subtype ≠ molecular genotype.

Bone fragility is universal in concept but highly variable in expression.

Fracture burden, deformity, stature, and extraskeletal findings differ.

The four familiar subtypes summarize phenotype rather than unique genes.

Slide 30 · Traditional four-subtype framework

Subtype

Clinical descriptor

Typical severity

I

Non-deforming, blue sclerae

Mild

II

Perinatally lethal

Extreme

III

Progressively deforming

Severe

IV

Variable, often normal sclerae

Intermediate

Clinical severity descriptors; Molecular diagnosis requires separate assessment.

Slide 31 · Type I: Clinical signature

Fractures often begin after birth during childhood.

Normal or near-normal stature is typical.

Blue sclerae and possible hearing or dental abnormalities may coexist.

Childhood fractures

Usually normal stature

Blue sclerae ± extraskeletal

Slide 32 · Type I: Evolution across life

Childhood fractures

Pubertal transition

Often fewer fractures

Fractures are prominent in childhood.

Fracture frequency often decreases after puberty.

Normal longevity is expected in this classic mild phenotype.

Slide 33 · Type I: Mechanism and clinical expression

Cause

Molecular effect

Reduced normal collagen

Quantitative defect

Expression

Typical phenotype

Blue sclerae

Mild bone fragility

Slide 34 · Type II: Most severe traditional category

The perinatally lethal phenotype can produce multiple intrauterine fractures.

Severe undermineralization, bone deformity, and a small thorax may occur.

Life-threatening respiratory insufficiency is central to outcome.

Extreme fragility

Multiple fetal fractures

Respiratory compromise

Slide 35 · Type II: Skeletal morphology

Long bones can appear crumpled, bowed, and severely shortened.

Multiple rib fractures may give beaded appearances on imaging.

These are radiologic findings; Schematic drawings are not diagnostic images.

Slide 36 · Type II: Understanding the textbook figure

Numerous fractures

Repeated deformation

Accordion-like shortening

A fetal radiograph with fractures in almost all bones.

Repeated fractures create accordion-like limb shortening.

The appearance conveys profound bone mechanical failure in utero.

Slide 37 · Type III: Survival with progressive deformity

Frequent fractures begin early, potentially including fetal life.

Marked growth impairment and deformity accumulate through childhood.

Progressive kyphoscoliosis is an important feature.

Early fractures

Progressive deformity

Short stature / kyphoscoliosis

Slide 38 · Type III: Longitudinal consequences

Early fracture burden

Growth-related deformity

Long-term functional impact

Bowed long bones and altered geometry affect mobility.

Spinal deformity may worsen with growth.

Dental, auditory, and scleral findings vary over time.

Slide 39 · Type IV: Intermediate expression

Skeletal

Bone features

Moderate fragility

Possible short stature

Extraskeletal

Extraskeletal signs

Normal sclerae common

Dental changes variable

Slide 40 · Scleral color is not a severity score

Blue sclerae may occur in both mild and severe forms.

Type IV may have a normal scleral appearance despite fractures.

Fractures, deformity, growth, and imaging are needed for severity assessment.

Slide 41 · Subtypes: Compact clinicopathologic map

Feature

I

II

III

IV

Skeletal severity

Mild

Extreme

Severe

Variable

Clinical pattern

Nondeforming

Perinatal lethal

Progressive deformity

Intermediate

Scleral hue

Often blue

Often blue

Variable

Often normal

Expected course

Normal lifespan

Perinatal lethal

Progressive

Survival usual

Slide 42 · Clinical classification has limitations

Use a subtype as a clinical shorthand—not a genetic test.

Different gene variants can produce overlapping skeletal phenotypes.

Features may change with age and intervention.

Modern records should distinguish clinical phenotype from confirmed molecular diagnosis.

Slide 43 · How OI enters the differential

Low-energy or recurrent fractures prompt investigation.

Examine stature, limb shape, sclerae, dentition, and ligamentous laxity.

Family history and developmental trajectory provide essential context.

Fracture history

Pattern of systemic signs

Targeted evaluation

Slide 44 · Physical examination: Clues with explanatory value

Fracture pattern

Connective-tissue clues

Growth/deformity

Disproportion between trauma and fracture severity suggests fragility.

Blue/gray sclerae and characteristic teeth support a collagenopathy.

Spinal curvature and limb bowing reflect cumulative skeletal effects.

Slide 45 · Radiography: Ask a structured question

Assess bone mass, cortex thickness, and long-bone geometry.

Document acute and healed fractures and spinal compression.

Interpret findings against age, severity, and alternative etiologies.

Density / cortex

Fracture burden

Bone geometry

Slide 46 · Imaging correlates by severity

Milder pattern

Mild disease

Thin cortices

Less deformity

Severe pattern

Severe disease

Repeated fractures

Bowing / thoracic changes

Slide 47 · Wormian bones and vertebral changes

Additional sutural bones can support OI but are not pathognomonic.

Vertebral compression can produce biconcave “codfish” bodies.

Findings require correlation with the clinical phenotype.

Slide 48 · Laboratory testing: What it cannot prove

In OI

Potentially normal

Calcium and phosphate

Vitamin D

Diagnostic role

Still required

Differential workup

Overall clinical correlation

Slide 49 · Molecular confirmation of collagen-related OI

Clinical phenotype

Molecular analysis

Variant interpretation

Integrated diagnosis

Suspected COL1A1/COL1A2-OI is evaluated with molecular genetic testing.

A pathogenic or likely pathogenic variant supports diagnosis with the phenotype.

A variant of uncertain significance alone is not diagnostic.

Slide 50 · Genetic panels versus a single-gene test

Focused approach

Targeted genes

COL1A1 / COL1A2

Classic collagen phenotype

Broader approach

Broader testing

Multiple OI genes

Atypical/unclear phenotype

Slide 51 · Genotype does not simply predict subtype

Pathogenic variants differ in position and functional effect.

Structural changes often produce more severe disease than reduction in synthesis.

Important phenotypic overlap and within-family variation remain.

Variant consequence

Matrix disruption

Variable phenotype

Slide 52 · Differential diagnosis: Recurrent fractures

Inherited collagenopathy

Metabolic bone disease

Trauma / other causes

Inherited OI is one important etiology—not the only one.

Other metabolic, mineralization, and acquired conditions may impair bone strength.

Concerning trauma histories require careful independent evaluation.

Slide 53 · Distinguish OI from osteopetrosis

OI

Osteogenesis imperfecta

Defective type I collagen

Usually low bone mass

Osteopetrosis

Osteopetrosis

Impaired osteoclast activity

Diffuse skeletal sclerosis

Slide 54 · The role of safeguarding in pediatric fractures

Neither “blue sclerae” nor recurrent fractures alone establish etiology.

OI must not be presumed from an isolated unexplained fracture.

Nonaccidental injury and genetic fragility may be difficult to distinguish.

Use a multidisciplinary, evidence-based assessment rather than a single sign.

Slide 55 · Case 1: Mild childhood fragility

Clinical findings

A school-aged child has recurrent low-impact fractures.

Examination shows blue sclerae and normal stature.

The phenotype suggests classic non-deforming OI (type I).

Interpretation

What collagen defect is classically associated?

Reduced production of otherwise normal type I collagen is a common explanation.

Slide 56 · Case 2: Severe prenatal presentation

Clinical findings

Fetal imaging reveals marked long-bone shortening and numerous fractures.

Rib deformity and a small chest are also present.

The pattern raises concern for perinatally lethal OI (type II).

Interpretation

Which outcome-determining organ system needs attention?

The respiratory system: Thoracic restriction and pulmonary compromise.

Slide 57 · Case 3: Progressive childhood deformity

Clinical findings

A child with fractures since infancy develops bowed limbs and kyphoscoliosis.

Growth restriction and functional limitation become prominent.

The course fits progressively deforming OI (type III).

Interpretation

What makes the subtype “progressively deforming”?

Cumulative fracture-related distortion across skeletal growth.

Slide 58 · Case 4: A normal sclera does not exclude OI

Clinical findings

A child has several fragility fractures, short stature, and normal sclerae.

Dentinogenesis imperfecta is also noted.

A common variable OI (type IV) phenotype remains plausible.

Interpretation

Which bedside shortcut is incorrect?

Excluding OI because the sclerae are not blue.

Slide 59 · Treatment follows the mechanical problem

Fracture care and deformity correction target skeletal consequences.

Rehabilitation seeks muscle strength, mobility, and preserved function.

Management requires tailoring to severity and age.

Fracture management

Rehabilitation

Function / participation

Slide 60 · Multidisciplinary surveillance

Musculoskeletal care

Dental care

Hearing / systemic care

Orthopedic and rehabilitation assessment address mobility and deformity.

Dental evaluation addresses dentinogenesis imperfecta.

Audiology and other specialty assessment address extraosseous burden.

Slide 61 · Pharmacologic therapy: Scope and limits

Bisphosphonates are commonly used in selected patients with significant skeletal burden.

The goal is improving bone health and reducing clinical complications.

Pharmacologic therapy does not replace collagen gene repair or multidisciplinary care.

Slide 62 · Genetic counseling integrates mechanism and family risk

Familial OI

Dominant variant present

Transmission is possible

Family testing relevant

Simplex OI

Single affected child

May be de novo

Mosaicism may matter

Slide 63 · Mechanism-to-manifestation synthesis

Collagen misfolding or inadequate synthesis weakens skeletal matrix.

The same connective-tissue defect can yield scleral, dental, auditory, and joint signs.

Molecular mechanism helps explain—but does not rigidly determine—severity.

Collagen abnormality

Weak bone matrix

Multisystem phenotype

Slide 64 · Questions that test understanding

Why can type I OI be comparatively mild despite a dominant variant?

How can a dominant-negative mechanism amplify collagen dysfunction?

Why are normal sclerae and normal routine chemistry not exclusion criteria?

Slide 65 · Core messages

OI is primarily a type I collagen-related skeletal fragility syndrome.

Quantity and quality defects help explain the phenotypic spectrum.

The four traditional types remain clinically useful but overlap genetically.

Diagnosis integrates clinical, radiographic, and molecular findings.

Slide 66 · Sources and interpretive boundaries

Robbins, Cotran & Kumar: Pathologic Basis of Disease. 11th edition.

Rodriguez Celin M, Steiner RD, Basel D. COL1A1- and COL1A2-Related Osteogenesis Imperfecta. GeneReviews.

MedlinePlus Genetics: Osteogenesis imperfecta.